Pharmaceutical company in
Zurich

Herb-pharma AG

Since 2008 · 1–10 empl.

Herb-pharma AG develops and manufactures cosmetics, nutritional products, medical devices and other health products. Its brands include Fytofontana, Virostop, Gyntima, Aurecon and Hemorrelax.

NORIS PHARMA AG

Since 2011 · 1–10 empl.

NORIS PHARMA AG develops and sells its own OTC products, medical devices and food supplements. It also supports partners with the development, production, registration and market launch of medicines, medical devices, food supplements and cosmetics.

MedComms Experts GmbH

Since 2012 · 11–20 empl.

MedComms Experts GmbH is part of Kinetix Health Group, which provides scientific communications for pharmaceutical and biotechnology companies. Its services include Medical Affairs strategy, medical content and digital solutions for engaging healthcare professionals.

SLC Bellevue GmbH

Since 2013 · 11–20 empl.

The core activity of SLC Bellevue GmbH - LUXES COSMETICS is the development, manufacture and marketing of natural cosmetics products, particularly skin care products, under the LUXES brand.

Alvotech Swiss AG

Since 2014 · 21–50 empl.

Alvotech Swiss AG develops and manufactures biosimilars, with a pipeline focused on monoclonal antibodies and other biologic medicines. The company follows a vertically integrated approach from R&D through drug product manufacturing and collaborates with commercial partners for market access.

Dr. Andres Pharma AG

Since 2015 · 11–20 empl.

Dr. Andres Pharma AG develops and manufactures herbal medicines and medical devices, including comfrey ointments and gels for muscle and joint complaints, as well as nasal ointments and hand disinfectants. Its fresh-plant products use medicinal herbs grown organically in Switzerland.

Advanz Pharma Specialty Medicine Switzerland GmbH

Since 2015 · 1–10 empl.

Advanz Pharma Specialty Medicine Switzerland GmbH is a pharmaceutical company that commercialises specialty, hospital and rare disease medicines. Its portfolio includes biosimilars, specialty generics and originator brands, and it works with biopharma and pharmaceutical development partners.

ph. AG

Since 2016 · 1–10 empl.

ph. AG offers nutritional products under the KA-EX brand for sport and recovery. Its core focus is on formulations for performance, recovery, stress regulation, and sleep quality, including powder sachets and ready-to-drink products with creatine, amino acids, and other ingredients.

swisscann tec AG

Since 2017 · 11–20 empl.

swisscann tec AG cultivates, processes and distributes THC-containing cannabis products for medical use. It supplies pharmacies, hospitals and pharmaceutical companies, and holds Swissmedic authorisations for pharmaceutical production and wholesale distribution.

Theramex Switzerland GmbH

Since 2017 · 11–20 empl.

Theramex Switzerland GmbH is a pharmaceutical company focused on women’s health, providing treatments and educational resources in areas such as contraception, menopause, osteoporosis and fertility.

Abela Pharm GmbH

Since 2018 · 1–10 empl.

Abela Pharm GmbH develops and manufactures pharmaceutical products, dietary supplements and medical devices. Its product range includes items for digestive health, coughs and colds, cardiovascular health, and vitamins and minerals.

Linkster Therapeutics AG

Since 2019 · 1–10 empl.

Linkster Therapeutics AG develops targeted therapeutics and drug candidates for diseases with unmet treatment needs. The biotechnology company uses its Flycode® technology and antibody platform to engineer antibody candidates and assess their properties and tissue-specific delivery.

Amicus Therapeutics Switzerland GmbH

Since 2019 · 11–20 empl.

Amicus Therapeutics Switzerland GmbH operates in the field of biotechnology medicines for rare genetic diseases. Its Swiss product offering includes Galafold (migalastat), a medicine for the treatment of Fabry disease.

Polpharma Biologics Switzerland AG

Since 2019 · 1–10 empl.

Polpharma Biologics Switzerland AG develops and manufactures biosimilars. The company supports biosimilars from scientific development through commercial supply and provides development and manufacturing services.

BEO Therapeutics AG

Since 2019 · 1–10 empl.

BEO Therapeutics AG develops oral microbiome therapies for diseases associated with metabolic waste products. Its areas of focus include gouty arthritis, metabolic diseases and chronic kidney disease; its candidate BEO 001 is being studied in clinical trials.

cellvie AG

Since 2020 · 11–20 empl.

cellvie AG develops biotechnology-based therapies using therapeutic mitochondria transplantation. The company is exploring its use to support cellular energy metabolism and as a vehicle for gene therapies, including applications in ischemia-reperfusion injury and epidermolysis bullosa.

Endogena Therapeutics AG

Since 2020 · 11–20 empl.

Endogena Therapeutics AG is a clinical-stage biotechnology company that discovers and develops medicines for endogenous regeneration. It uses small molecules to regulate the body’s own stem and progenitor cells and is developing treatments for degenerative diseases, including retinal disorders.

Denali Therapeutics CH GmbH

Since 2021 · 1–10 empl.

Denali Therapeutics CH GmbH is a biopharmaceutical company that discovers, develops and delivers biotherapeutics intended to treat serious diseases affecting the brain and the body. It developed the TransportVehicle™ platform to enable systemic delivery of enzymes, oligonucleotides and antibodies across the blood–brain barrier and is advancing a pipeline for neurodegenerative and lysosomal storage disorders.

Biocon Biologics Switzerland AG

Since 2023 · 1–10 empl.

Biocon Biologics Switzerland AG is a biosimilars company active in the development, manufacturing and commercialization of biologic therapies. Its portfolio includes insulins, monoclonal antibodies and conjugated recombinant proteins for indications such as diabetes, cancer, autoimmune diseases and serious eye conditions.

Isomorphic Labs Switzerland AG

Since 2023 · 1–10 empl.

Isomorphic Labs Switzerland AG develops AI-based technologies to accelerate drug discovery and development. The company operates a unified drug‑design engine using predictive and generative models to run in‑silico experiments, participates in research collaborations with pharmaceutical companies, and advances an internal pipeline focused on oncology and immunology.

Perrigo Schweiz AG

Since 1979 · 1–10 empl.

MetrioPharm AG

Since 2002 · 11–20 empl.

The core activity of MetrioPharm AG is the development of medications against chronic inflammatory diseases such as psoriasis, arthritis and multiple sclerosis.

Acino International AG

Since 1962 · 101–500 empl.·4.0(4)

Acino International AG is a pharmaceutical company that develops, manufactures and markets medicines. It distributes products in selected markets in Africa, Latin America, the Middle East and Türkiye, Ukraine and other Eurasian countries, and offers contract manufacturing, licensing and distribution partnerships.

Ultimate Medicine AG

Since 2020 · 11–20 empl.

Ultimate Medicine AG is a preclinical biotechnology company developing an oral small-molecule therapy for Alzheimer’s disease. Its lead program, UM01, is designed to inhibit the production of a gut-bacteria-derived metabolite implicated in the disease.

Melisana AG

Since 1997 · 21–50 empl.·5.0(1)

The core activity of Melisana AG is the marketing of over-the-counter medicinal products, dietary supplements and cosmetic products for self-medication, particularly in the Consumer Healthcare sector.

Boehringer Ingelheim Veterinary Medicine Switzerland AG

Since 2024 · 1–10 empl.

Boehringer Ingelheim Veterinary Medicine Switzerland AG is part of Boehringer Ingelheim and is active in the discovery, development, manufacture and marketing of health care products. Its Animal Health business focuses on the prediction, prevention and treatment of diseases in animals, as well as products for different animal species.

Selectchemie AG

Since 1969 · 51–100 empl.·3.7(3)

Selectchemie AG supplies the pharmaceutical industry with active pharmaceutical ingredients and excipients, and develops and manufactures generic medicines for human use. It also provides technical, scientific, regulatory and commercial support, including services for regulatory dossiers, sourcing and supply chains.

EvlaBio AG

Since 2022 · 11–20 empl.

EvlaBio AG develops a monoclonal antibody therapy for left ventricular hypertrophy associated with chronic kidney disease. Its approach is designed to selectively inhibit FGF23-driven activation of the FGFR4 receptor.

Medropharm AG

Since 2014 · 1–10 empl.·5.0(2)

Medropharm AG develops and processes cannabis and other medicinal plants for pharmaceutical applications and the food, cosmetics and animal-feed industries. Its services include GACP-compliant cultivation, GMP processing and extraction, contract manufacturing, product development, regulatory support, storage and distribution.

CNBS Unlimited GmbH

Since 2021 · 1–10 empl.

CNBS Unlimited GmbH operates Cannabis Sommelier, an online and retail business selling CBD hemp products and accessories. Its range includes CBD flowers, oils and extracts, as well as vaporizers, dabbing devices and headshop products; bulk quantities are also available to trade customers.

Apricot Therapeutics AG

Since 2022 · 1–10 empl.

Apricot Therapeutics AG develops an image-based platform for functional drug response profiling in precision oncology. Using multiplex microscopy, image processing and biomarkers, it analyses how individual cancer cells respond to different anti-cancer drugs and produces drug response profiles for each sample.

swisscann pharma GmbH

Since 2023 · 11–20 empl.

swisscann pharma GmbH operates in the medical cannabis sector. Swisscann distributes THC-containing cannabis products for medical use to pharmacies, hospitals and pharmaceutical companies; the products are made at a GMP-certified production facility.

Pfizer AG

Since 2001 · 101–500 empl.·2.8(25)

Pfizer AG is a research-based pharmaceutical company that researches and develops therapies and vaccines. It offers medicines and vaccines and conducts scientific research and clinical studies.

Xlife Sciences Innovation GmbH

Since 2025 · 1–10 empl.

Xlife Sciences Innovation GmbH is a Swiss life sciences company that actively develops research projects from academic and industrial environments and supports them through to commercialization. The company identifies early-stage innovations and works with universities, research institutions, and industry partners.

Evax AG

Since 2024 · 11–20 empl.·4.9(7)

Evax AG develops therapeutic vaccines for horses, particularly for chronic conditions such as allergies and respiratory diseases. It also sells horse-care products, with sales supporting further therapy development.

Nuantic AG

Since 2025 · 1–10 empl.

Nuantic AG develops computational methods to optimize therapeutic proteins and peptides. Its AI methods design variants with targeted improvements in properties such as binding affinity, stability and immunogenicity for subsequent laboratory testing.

MagnaPharm Switzerland GmbH

Since 2026 · 1–10 empl.

MagnaPharm Switzerland GmbH is a pharmaceutical company providing a broad range of services in sales, market access, marketing, medical promotion, and regulatory services. The company also covers multiple pharmaceutical and healthcare product categories, including Rx and OTC drugs, food supplements, medical devices, contrast media, and dermo-cosmetics.

REMUUN AG

Since 2025 · 1–10 empl.

REMUUN AG develops therapeutic monoclonal antibodies using its MEGA antibody-development platform. The company focuses on antibody-based therapies for human medicine.